Min Gyu Lee, Ph.D.
Department of Molecular and Cellular Oncology, Division of Discovery Science
Present Title & Affiliation
Primary Appointment
Professor, Department of Molecular and Cellular Oncology, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, TX
Regular member, Department of Graduate School of Biomedical Sciences (GSBS), The MD Anderson UTHealth Houston Graduate School, Houston, Texas
Faculty, Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Research interests: The role of histone-modifying enzymes
Key Words: Histone modifications, Histone-modifying enzymes, Gene regulation,
Epigenetics, Tumor suppression & Cancer
My laboratory is interested in understanding the role of histone modifications. Histone modifications include methylation, acetylation, phosphorylation and ubiquitylation, and play an essential role in regulating gene expression and chromatin architecture, consequently affecting numerous biological processes such as cellular differentiation, development and tumorigenesis.
It has been increasingly evident that epigenetic changes ― changes in a phenotype without altering DNA sequence ― are a common basis for cancer phenotype. While the link between epigenetic aberration and cancer development is clear, the epigenetic mechanisms underlying oncogenic processes remain to be studied. Recently, changes in histone modifications have been emerged as a key player in epigenetic alteration involved in the oncogenic events such as inactivation of tumor suppression pathways and activation of oncogenes.
Since histone modifications are controlled by a cohort of histone-modifying enzymes, we primarily explore the biochemical and biological role of histone-modifying enzymes, especially with an emphasis on histone methyltransferases and demethylases. In parallel, we also study the epigenetic role of these enzymes in the oncogenic events or tumor suppression pathways.
Education & Training
Degree-Granting Education
| 2003 | Johns Hopkins University, School of Medicine, Baltimore, Maryland, US, Biological Chemistry, Dr. Peter L Pedersen, Ph.D |
| 1993 | Seoul National University, Seoul, Agricultural Chemistry, M.S |
| 1991 | Seoul National University, Seoul, Agricultural Chemistry, BS |
Postgraduate Training
| 2004-2007 | Research Fellowship, The Wistar Institute, Philadelphia, Pennsylvania |
| 2003-2004 | Research Fellowship, Johns Hopkins University, Baltimore, Maryland |
Experience & Service
Faculty Academic Appointments
Associate Professor, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2021
Assistant Professor, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2015
Staff Scientist, The Wistar Institute, Philadelphia, PA, 2007 - 2008
Other Professional Positions
Researcher, Hyundai Pharmaceutical Industrial Co., Ltd, Bucheon, 1993 - 1998
Honors & Awards
| 2011 | Cancer Center Support Grant Faculty Development Award |
| 2008 | Christopher Davis Fellowship Memorial Award |
| 1988 - 1991 | University Honor Student, Seoul National University, South Korea |
| 1987 - 1991 | Cheonbuk-aehyang Foundation Scholarship |
Professional Memberships
Selected Presentations & Talks
Formal Peers
- 2022. Epigenetic Aberrations and Oncogenesis Mechanisms. Invited. West Lafayette, IN, US.
- 2022. Epigenetic Oncogenesis Mechanisms. Visiting. Houston, TX, US.
- 2022. Altered Epigenetic Pathways for Tumorigenesis. Invited. Indianapolis, IN, US.
- 2021. Epigenetic Mechanisms for Tumorigenesis. Invited. Buffalo, NY, US.
- 2021. Epigenetic Alterations and Tumorigenesis Mechanisms. Invited. Ann Harbor, MI, US.
- 2021. Tumor-Suppressive Function of the Epigenetic Modifier MLL4 (Virtual). Visiting, US.
- 2021. Epigenetic Mechanisms of Tumor Suppression. Invited. Waco, TX, US.
- 2019. Epigenetic Modifiers in Cancer and Metastasis. Invited. Houston, TX, US.
- 2019. Epigenetic Regulators, Cancer, and Metastasis. Invited.
- 2019. Epigenetic Regulators, Tumorigenesis, and Metastasis. Invited.
- 2019. Epigenetic Modulators, Cancer, and Metastasis. Invited. Philadelphia, PA, US.
- 2019. Epigenetic Regulators, Tumorigenesis and Metastasis. Invited. Minneapolis, MN, US.
- 2018. Epigenomic Modifiers, Cancer and Metastasis. Invited.
- 2017. Histone Modifiers in Cancer and Metastasis. Invited. Bethesda, MD, US.
- 2015. Epigenetic Histone Methylation Modifiers in Cancer and Stem Cells. Invited. Miami, FL, US.
- 2015. Epigenetic Roles of Histone Methylation Modifiers in Cancer and Differentiation. Invited. Houston, US.
- 2014. Epigenetic Roles of Histone Methylation Modifiers in Cancer and Differentiation. Invited.
- 2014. Epigenetic Roles of Histone Methylation Modifiers in Cancer and Differentiation. Invited.
- 2014. Epigenetic Roles of Histone Methylation Modifiers in Cancer and Differentiation. Invited.
- 2014. Epigenetic Roles of Histone Methylation Modifiers in Cancer and Differentiation. Invited.
- 2013. Epigenetic Roles of Histone Methylation Modifiers in Cancer and Differentiation. Visiting. Houston, TX, US.
- 2013. Roles of Histone Methylation Modifiers in Cancer and Cellular Differentiation. Visiting. Houston, TX, US.
- 2013. Diverse Roles of Histone Methylation Modifiers in Cancer and Differentiation. Visiting. Houston, TX, US.
- 2010. Epigenetic Roles of Histone Lysine Demethylases. Invited. Houston, TX, US.
- 2008. Histone Lysine Demethylation and Its Role in Chromatin Function. Visiting. Houston, TX, US.
- 2008. Histone Lysine Demethylation and Its Role in Chromatin Function. Invited. Chapel Hill, NC, US.
- 2008. Histone Lysine Demethylation and Its Role in Chromatin Function. Invited. Dallas, TX, US.
- 2007. Histone Lysine Demethylation and Its Role in Chromatin Function. Invited. Irvine, CA, US.
- 2006. Histone Demethylation and Its Role in Chromatin Function. Invited. Philadelphia, PA, US.
- 2006. Histone Demethylation and Its Role in Gene Regulation. Invited.
- 2006. Histone Demethylation and Its Role in Gene Regulation. Invited. Birmingham, AL, US.
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | The Epigenetic Regulator JARID1D in Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R01CA303327 |
| Date: | 2025 - 2030 |
| Title: | MLL4-mediated temporal regulation of epigenomic and transcriptional programs in cerebellar neurons |
| Funding Source: | NIH/NINDS |
| Role: | PI |
| ID: | 1R01NS136211 |
| Date: | 2024 - 2026 |
| Title: | UTEP/UTMDACC Partnership for Hispanic Cancer Disparities Research |
| Funding Source: | CPRIT |
| Role: | Mentor |
| ID: | RP210153 |
| Date: | 2024 - 2025 |
| Title: | MLL4-mediated temporal regulation of epigenomic and transcriptional programs in cerebellar neurons |
| Funding Source: | UT MDACC |
| Role: | PI |
| ID: | RCTS 2024-00063613-Y1 |
| Date: | 2023 - 2028 |
| Title: | CRACD-controlled cell plasticity and small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA278967-01A1 |
| Date: | 2022 - 2027 |
| Title: | Heterozygous KMT2D Loss and Medulloblastoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA262324-01A1 |
| Date: | 2021 - 2024 |
| Title: | Targeting Histone Lysine Demethylase KDM4A in Neuroendocrine Prostate Cancer |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Co-I |
| ID: | W81XWH-21-1-0522 |
| Date: | 2021 - 2023 |
| Title: | Heterozygous KMT2D Loss and Medulloblastoma |
| Funding Source: | UT MD Anderson Cancer Center |
| Role: | PI |
| ID: | RCTS 2021-00059811-Y1 |
| Date: | 2020 - 2025 |
| Title: | PAF-Remodeled DREAM Complex in Cancer and Regeneration |
| Funding Source: | NCI |
| Role: | Co-I |
| ID: | 2R01CA193297 |
| Date: | 2018 - 2021 |
| Title: | Center for Cancer Epigenetics (CCE)'s Solexa Allowance |
| Funding Source: | The University of Texas M. D. Anderson Cancer Center |
| Role: | Principal Investigator-MDACC |
| Date: | 2017 - 2023 |
| Title: | Role of the Histone Modifier KDM2A in Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA207098-01A1 |
| Date: | 2017 - 2023 |
| Title: | Role of the Histone Methyltransferase MLL4 in Medulloblastoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA207109-01A1 |
| Date: | 2016 - 2017 |
| Title: | Targeting p53 in cancer through manipulation of p63 and p73 (From Dr. Elsa Flores) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP140271 |
| Date: | 2014 - 2017 |
| Title: | Innovative epigenetics therapies project |
| Funding Source: | Cancer for Epigenetics Center at University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2013 - 2015 |
| Title: | Epigenetics Center Pilot Project Fund |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2011 - 2016 |
| Title: | Role of the Histone Modifier KDM6A in Stem Cell Differentiation |
| Funding Source: | NIH/NIGMS |
| Role: | PI |
| ID: | 1R01GM095659 |
| Date: | 2011 - 2017 |
| Title: | Role of the Histone Demethylase JARID1d in Epigenetic Events of Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01 CA157919-01 |
| Date: | 2010 - 2011 |
| Title: | CCE Pilot Project Fund |
| Funding Source: | The University of Texas M. D. Anderson Cancer Center |
| Role: | Principal Investigator-MDACC |
| Date: | 2010 - 2014 |
| Title: | Role of the Histone Demethylase UTX in Breast Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP110183 |
| Date: | 2010 - 2011 |
| Title: | CCSG Faculty Development Fund |
| Funding Source: | The University of Texas M. D. Anderson Cancer Center |
| Role: | Principal Investigator-MDACC |
| Date: | 2009 - 2013 |
| Title: | Solexa Sequencing allowance |
| Funding Source: | Cancer for Epigenetics Center at University of Texas M. D. Anderson Cancer Center |
| Role: | PI |
| Date: | 2009 - 2015 |
| Title: | Startup Fund |
| Funding Source: | The University of Texas M. D. Anderson Cancer Center |
| Role: | Principal Investigator-MDACC |
Selected Publications
Peer-Reviewed Articles
- Song, S, Fan, Y, Zou, G, Huo, L, Kumar, J, Li, Y, Wang, R, Dai, E, Jin, J, Scott, AW, Shao, SH, Pizzi, M, Vykoukal, JV, Katayama, H, Hanash, S, Calin, GA, Zhang, X, Lee, MG, Wang, Z, Lo, Y, Gan, Q, Waters, R, Yin, F, Wang, L, Cheng, X, Ajani, JA, Dhar, SS. KAP1 promotes gastric adenocarcinoma progression by activating Hippo/YAP1 signaling via binding to HNRNPAB. Cancer Letters 621, 2025. e-Pub 2025. PMID: 40189014.
- Dhar, SS, Brown, CA, Rizvi, A, Reed, L, Kotla, S, Zod, C, Abraham, J, Abe, J, Rajaram, V, Chen, K, Lee, MG. Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS. Cell Reports 44(5), 2025. e-Pub 2025. PMID: 40286267.
- Cai, L, Wu, F, Zhou, Q, Gao, Y, Yao, B, Deberardinis, RJ, Acquaah-Mensah, G, Aidinis, V, Beane, J, Biswal, S, Chen, T, Concepcion-Crisol, CP, Grüner, BM, Jia, D, Jones, RA, Kurie, JM, Lee, MG, Lindahl, P, Lissanu, Y, Lorz, C, MacPherson, D, Martinelli, R, Mazur, PK, Mazzilli, SA, Mii, S, Moll, HP, Moorehead, RA, Morrisey, EE, Ng, SR, Oser, M, Pandiri, AR, Powell, CA, Ramadori, G, Santos, M, Snyder, EL, Sotillo, R, Su, KY, Taki, T, Taparra, K, Tran, PT, Xia, Y, Van Veen, JE, Winslow, MM, Xiao, G, Rudin, CM, Oliver, TG, Xie, Y, Minna, J. The Lung Cancer Autochthonous Model Gene Expression Database Enables Cross-Study Comparisons of the Transcriptomic Landscapes Across Mouse Models. Cancer Research 85(10):1769-1783, 2025. e-Pub 2025. PMID: 40298430.
- Dhar SS, Brown C, Rizvi A, Reed L, Kotla S, Zod C, Abraham J, Abe JI, Rajaram V, Chen K, Lee MG. Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of lysine demethylation and oxidative phosphorylation. bioRxiv, 2023. e-Pub 2023. PMID: 37961118.
- George J, Chen Y, Abdelfattah N, Yamamoto K, Gallup TD, Adamson SI, Rybinski B, Srivastava A, Kumar P, Lee MG, Baskin DS, Jiang W, Choi JM, Flavahan W, Chuang JH, Kim BY, Xu J, Jung SY, Yun K. Cancer stem cells, not bulk tumor cells, determine mechanisms of resistance to SMO inhibitors. Cancer Res Commun 2(6):402-416, 2022. e-Pub 2022. PMID: 36688010.
- M‡ N, S‡ W, Gore B, Abbas H, Lee K, Checker R, Dhar SS, Rajapakshe K, Tan AC, Lee MG*, Coarfa C*, Flores ER*. ΔNp63 executes an oncogenic program through the regulation of common landscape of enhancer associated genes in non-small cell lung cancer. Nature Communications (*Co-Corresponding author) 13(1):614, 2022. e-Pub 2022. PMID: 35105868.
- Wang G, Xia B, Zhou M, Lv J, Zhao D, Li Y, Bu Y, Wang X, Cooke JP, Cao Q, Lee MG, Zhang L, Chen K. MACMIC Reveals A Dual Role of CTCF in Epigenetic Regulation of Cell Identity Genes. Genomics Proteomics Bioinformatics 19(1):140-153, 2021. e-Pub 2021. PMID: 33677108.
- Zhao D, Zhang L, Zhang M, Xia B, Lv J, Wang G, Meng Q, Yi Y, Zhu S, Tomoiaga AS, Lee MG, Cooke JP, Cao Q, Chen K. Broad Genic Repression Domains Signify Enhanced Silencing of Oncogenes. Nature Communications 11(1),5560, 2020. e-Pub 2020.
- Wu X, Park M, Sarbassova DA, Ying H, Lee MG, Bhattacharya R, Ellis L, Peterson CB, Hung MC, Lin HK, Bersimbaev RI, Song MS, Sarbassov DD. A Chirality-Dependent Action of Vitamin C in Suppressing KRAS Mutant Tumor Growth by the Oxidative Combination: Rationale for Cancer Therapeutics. Int J Cancer doi: 10.1002/ijc.32658, 2020. e-Pub 2020.
- Alam H, Tang M, Maitituoheti M, Dhar SS, Kumar M, Han CY, Ambati CR, Amin SB, Gu B, Chen TY, Lin YH, Chen J, Muller FL, Putluri N, Flores ER, DeMayo FJ, Baseler L, Rai K, Lee MG. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer. Cancer Cell 37(4):599-617, 2020. e-Pub 2020. PMID: 32243837.
- Maitituoheti M, Keung E, Tang M, Yan L, Alam H, Han G, Raman A, Terranova C, Sarkar S, Orouji E, Amin S, Sharma S, Williams M, Samant NS, Dhamdhere M, Zhang N, Shah T, Shah A, Axelrad JB, Esmaeili-Anvar N, Lin YH, Jiang S, Chang QE, Ingram DR, Wang WL, Lazar A, Lee MG, Muller F, Wang L, Ying H, Rai K. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF signaling in KMT2D Mutant Melanoma. Cell Reports 33(3), 108293, 2020. e-Pub 2020.
- Park MK, Yao Y, Xia W, Setijono SR, Kim JH, Vila IK, Chiu HH, Wu Y, Billalabeitia EG, Lee MG, Kalb RG, Hung MC, Pandolfi PP, Song SJ, Song MS. PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression. Nature Communications 10(1):636, 2019. e-Pub 2019. PMID: 30733438.
- Wang G, Long J, Gao Y, Zhang W, Han F, Xu C, Sun L, Yang SC, Lan J, Hou Z, Cai Z, Jin G, Hsu CC, Wang YH, Hu J, Chen TY, Li H, Lee MG, Lin HK. SETDB1-mediated methylation of Akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis. Nature Cell Biology 21(2):214-225, 2019. e-Pub 2019. PMID: 30692626.
- Liu Y, Qin S, Chen TY, Lei M, Dhar SS, Ho JC, Dong A, Loppnau P, Li Y, MG* L, J* M. Structural insights into trans-histone regulation of H3K4 methylation by unique histone H4 binding of MLL3/4. Nature Communications (*Co-Corresponding author) 10(1):36, 2019. e-Pub 2019. PMID: 30604749.
- Alam H, Li N, Dhar SS, Wu SJ, Lv J, Chen K, Flores ER, Baseler L, Lee MG. HP1γ promotes lung adenocarcinoma by downregulating the transcription-repressive regulators NCOR2 and ZBTB7A. Cancer Research 78(14):3834-3848, 2018. e-Pub 2018. PMID: 29764865.
- Dhar SS, Zhao D, Lin T, Gu B, Pal K, Wu SJ, Alam H, Lv J, Yun K, Gopalakrishnan V, Flores ER, Northcott PA, Rajaram V, Li W, Shilatifard A, Sillitoe RV, Chen K, Lee MG. MLL4 Is Required to Maintain Broad H3K4me3 Peaks and Super-Enhancers at Tumor Suppressor Genes. Molecular Cell 70(5):825-841.e6, 2018. e-Pub 2018. PMID: 29861161.
- Chen TY, Lee SH, Dhar SS, Lee MG. Protein arginine methyltransferase 7-mediated microRNA-221 repression maintains Oct4, Nanog, and Sox2 levels in mouse embryonic stem cells. J Biol Chem 293(11):3925-3936, 2018. e-Pub 2018. PMID: 29378844.
- Taube JH, Sphyris N, Johnson KS, Reisenauer KN, Nesbit TA, Joseph R, Vijay GV, Sarkar TR, Bhangre NA, Song JJ, Chang JT, Lee MG, Soundararajan R, Mani SA. The H3K27me3-demethylase KDM6A is suppressed in breast cancer stem-like cells, and enables the resolution of bivalency during the mesenchymal-epithelial transition. Oncotarget 8(39):65548-65565, 2017. e-Pub 2017. PMID: 29029452.
- Lee SH, Chen TY, Dhar SS, Gu B, Chen K, Kim YZ, Li W, Lee MG. A feedback loop comprising PRMT7 and miR-24-2 interplays with Oct4, Nanog, Klf4 and c-Myc to regulate stemness. Nucleic Acids Research 44(22):10603-10618, 2016. e-Pub 2016. PMID: 27625395.
- Li N, Li Y, Lv J, Zheng X, Wen H, Shen H, Zhu G, Chen TY, Dhar SS, Kan PY, Wang Z, Shiekhattar R, Shi X, Lan F, Chen K, Li W, Li H, Lee MG. ZMYND8 Reads the Dual Histone Mark H3K4me1-H3K14ac to Antagonize the Expression of Metastasis-Linked Genes. Molecular Cell 63(3):470-84, 2016. e-Pub 2016.
- Dhar SS, Lee SH, Chen K, Zhu G, Oh W, Allton K, Gafni O, Kim YZ, Tomoiga AS, Barton MC, Hanna JH, Wang Z, Li W, Lee MG. An essential role for UTX in resolution and activation of bivalent promoters. Nucleic Acids Research 8(8):3659-74, 2016. e-Pub 2016.
- Li N, Dhar SS, Chen TY, Kan PY, Wei Y, Kim JH, Chan CH, Lin HK, Hung MC, Lee MG. JARID1D is a suppressor and prognostic marker of prostate cancer invasion and metastasis. Cancer Research 76(4):831-43, 2016. e-Pub 2016.
- Dhar SS, Alam H, Li N, Wagner KW, Chung J, Ahn YW, Lee MG. Transcriptional Repression of Histone Deacetylase 3 by the Histone Demethylase KDM2A Is Coupled to Tumorigenicity of Lung Cancer Cells. J Biol Chem 289:7483-7496, 2014. e-Pub 2014.
- Kim J, Sharma A, Dhar SS, Lee S, Gu B, Chan CH, Lin HK, Lee MG. UTX and MLL4 Coordinately Regulate Transcriptional Programs for Cell Proliferation and Invasiveness in Breast Cancer Cells. Cancer Research 74(6):1705-17, 2014. e-Pub 2014. PMID: 24491801.
- Wagner K, Alam H, Dhar S, Giri U, Li N, Wei Y, Giri D, Cascone T, Kim JH, Ye Y, Multani A, Chan CH, Erez B, Saigal B, Chung J, Lin HK, Wu X, Hung M, Heymach J, Lee MG. KDM2A Promotes Lung Tumorigenesis by Epigenetically Enhancing ERK1/2 Signaling. J Clin Invest 123:5231-5246, 2013. e-Pub 2013.
- Dhar SS, Lee SH, Kan PY, Voigt P, Ma L, Shi X, Reinberg D, Lee MG. Trans-tail regulation of MLL4-catalyzed H3K4 methylation by H4R3 symmetric dimethylation is mediated by a tandem PHD of MLL4. Genes Dev 26(24):2749-62, 2012. e-Pub 2012. PMID: 23249737.
- Wen H, Li J, Song T, Lu M, Kan PY, Lee MG, Sha B, Shi X. Recognition of histone H3K4 trimethylation by the plant homeodomain of PHF2 modulates histone demethylation. J Biol Chem 285(13):9322-6, 2010. e-Pub 2010. PMID: 20129925.
- Smith ER, Lee MG, Winter B, Droz NM, Eissenberg JC, Shiekhattar R, Shilatifard A. Drosophila UTX is a histone H3 Lys27 demethylase that colocalizes with the elongating form of RNA polymerase II. Mol Cell Biol 28(3):1041-6, 2008. e-Pub 2008. PMID: 18039863.
- Ingvarsdottir K, Edwards C, Lee MG, Lee JS, Schultz DC, Shilatifard A, Shiekhattar R, Berger SL. Histone H3 K4 demethylation during activation and attenuation of GAL1 transcription in Saccharomyces cerevisiae. Mol Cell Biol 27(22):7856-64, 2007. e-Pub 2007. PMID: 17875926.
- Lee MG, Villa R, Trojer P, Norman J, Yan KP, Reinberg D, Di Croce L, Shiekhattar R. Demethylation of H3K27 Regulates Polycomb Recruitment and H2A Ubiquitination. Science 318(5849):447-50, 2007. e-Pub 2007. PMID: 17761849.
- Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL. p53 is regulated by the lysine demethylase LSD1. Nature 449(7158):105-8, 2007. e-Pub 2007. PMID: 17805299.
- Eissenberg JC, Lee MG, Schneider J, Ilvarsonn A, Shiekhattar R, Shilatifard A. The trithorax-group gene in Drosophila little imaginal discs encodes a trimethylated histone H3 Lys4 demethylase. Nature Structural & Molecular Biology 14(4):344-6, 2007. e-Pub 2007. PMID: 17351630.
- Lee MG, Norman J, Shilatifard A, Shiekhattar R. Physical and functional association of a trimethyl H3K4 demethylase and Ring6a/MBLR, a polycomb-like protein. Cell 128(5):877-887, 2007. e-Pub 2007. PMID: 17320162.
- Nicolas E, Lee MG, Hakimi MA, Cam HP, Grewal SI, Shiekhattar R. Fission yeast homologs of human histone H3 lysine 4 demethylase regulate a common set of genes with diverse functions. J Biol Chem 281(47):35983-8, 2006. e-Pub 2006. PMID: 16990277.
- Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol 13(6):563-7, 2006. e-Pub 2006. PMID: 16793513.
- Lee MG, Wynder C, Bochar DA, Hakimi MA, Cooch N, Shiekhattar R. Functional interplay between histone demethylase and deacetylase enzymes. Mol Cell Biol 26(17):6395-6402, 2006. e-Pub 2006. PMID: 16914725.
- Lee MG, Wynder C, Norman J, Shiekhattar R. Isolation and characterization of histone H3 lysine 4 demethylase-containing complexes. Methods 40(4):327-30, 2006. e-Pub 2006. PMID: 17101444.
- Lee MG, Wynder C, Cooch N, Shiekhattar R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 437(7057):432-5, 2005. e-Pub 2005. PMID: 16079794.
- Lee MG, Pedersen PL. Glucose metabolism in cancer: importance of transcription factor-DNA interactions within a short segment of the proximal region of the type II hexokinase promoter. J Biol Chem 278(42):41047-58, 2003. e-Pub 2003. PMID: 12893819.
Invited Articles
- Dhar SS, Lee MG. Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors. Oncotarget 12(13):1296-1308, 2021. e-Pub 2021. PMID: 34194626.
- Gu B, Lee MG. Histone H3 Lysine 4 Methyltransferases and Demethylases in Self-renewal and Differentiation of Stem Cells. Cell & Bioscience 3(1):39, 2013. e-Pub 2013. PMID: 24172249.
Review Articles
- Alam H, Gu B, Lee MG. Histone methylation modifiers in cellular signaling pathways. Cell Mol Life Sci 72(23):4577-92, 2015. e-Pub 2015. PMID: 26305020.
Patient Reviews
CV information above last modified September 17, 2025